HI-Bio was established on the premise that treatments for immune-mediated illnesses have the potential to provide patients with better outcomes. Many IMDs are caused by immune system cells, such as mast cells, neutrophils, plasma cells, and more, which are dysfunctional. These cells are in charge of crucial processes and functions. With the useof medicines, HI-efforts Bio uses a precision medicine strategy to target, modify or deplete key cellular disease drivers.HI-Bio was established in 2021 in San Francisco, California.

Biotechnology

Health Care

Life Sciences

Therapeutics

HI-Bio

Travis Murdoch, MD

Lorna Dean

Melisa Martin

Matthew Albert, MD, PhD

Joyce Liaw

Houston Gilbert

Gijsbert Grotenbreg

Donna Flesher

David Schisla

The Research & Development team at HI-Bio is focused on discovering and developing precision medicines to target and modify key cellular drivers of immune-mediated diseases. The team conducts cutting-edge research in immunology, antibody engineering, and translational sciences to innovate effective treatments and improve patient outcomes.

Research & Development

Development and Clinical Operations

Leadership Team

Research & Development

About

Team members

Other teams at HI-Bio

Development and Clinical Operations

Leadership Team